This suggests that endogenous SIRPα in melanoma cells plays a positive role in PD-1/PD-L1-induced T-cell-mediated anticancer immunity, while the absence of SIRPα may lead to increased resistance to PD-L1 therapy (66). This evidence concerns the gene SIRPA and melanoma.